3 New Strong Buy Ratings from Top-Rated Analysts: 02/25/2025
WallStreetZen has a line on what Wall Street’s top-rated analysts are watching right now. Our picks for today?
- Operating margins expanded significantly for GE Healthcare Technologies Inc (NASDAQ: GEHC) — and analysts like what they see.
- Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) gets a hefty price target increase after announcing earnings.
- Wyndham Hotels & Resorts Inc (NYSE: WH) only earns Buy and Strong Buy ratings among the analysts we track. (This is not common)
Love these alerts? Get more every day: Try WallStreetZen Premium
1- Ge Healthcare Technologies Inc (NASDAQ: GEHC)
Spun off of General Electric back in early 2023, our second entry is a business that provides medical imaging, diagnostics, and patient monitoring systems in hospitals and clinics in more than 160 countries across the world. The company’s latest earnings call was better than expected — and two eminent analysts recently gave GEHC their seal of approval.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $92.52 — get current quote >
Max 1-year forecast: $110.00
Why we’re watching:
- Ge Healthcare Technologies enjoys broad, nearly unanimous support from equity researchers. At present, 8 analysts track GEHC stock and issue ratings for it — 5 rate it a Strong Buy, while the rest of the ratings are evenly split between Buy, Hold, and Strong Sell — with 1 each. See the ratings
- Citigroup’s Joanne Wuensch (a top 6% rated analyst) reiterated an earlier Strong Buy rating on February 13, after the company released its Q4 and FY 2024 report. She raised her price target from $103 to $110.
- Earnings per share came in above estimates — while revenues missed forecasts by just 0.25%.
- Wuensch summarized the quarter thusly: Operating margins expanded "significantly." in Q4, driving EPS ahead of consensus, while total company organic order increased by 6% Y/Y — and an increase in book-to-bill ratio reflects continued product demand.
- Looking ahead, the analyst said management's FY 2025 guidance "seems conservative."
- Much of the same was echoed by Larry Biegelsen of Wells Fargo (a top 8% rated analyst), who also doubled down on a previous Strong Buy rating and increased his price target from $96 to $103.
- Regarding guidance, the analyst told readers that management expects headwinds in China to slow growth in that market in 1H 2025. Management also expects growth in China in 2H 2025, resulting in FY 2025 in the market to be down in the low single digits.
- GEHC carries an overall Zen Rating of B — indicating that it ranks in the top 20% of all the stocks tracked by our proprietary quant system.
- A particular highlight is the stock’s Safety Component Grade rating of A — in this category, Ge Healthcare ranks in the 99th percentile, indicating extremely consistent earnings and operational metrics. (See all 7 Zen Component Grades here >)
2- Jazz Pharmaceuticals PLC (NASDAQ: JAZZ)
You might think that this is yet another ambitious, risky biotech startup — and you’d be wrong, Jazz Pharmaceuticals has been in business for 22 years — and maintains a portfolio of leading treatments in neurology, oncology, and several rare medical issues. At present, JAZZ stock represents a very rare blend of growth and value — one that merits closer consideration.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $134.96 — get current quote >
Max 1-year forecast: $207.00
Why we’re watching:
- Wall Street is unequivocally bullish on JAZZ — a consensus Strong Buy, the stock carries 4 Strong Buy ratings and 4 Buy ratings. See the ratings
- Wells Fargo researcher Mohit Bansal (a top 14% rated analyst) upgraded the stock from a Buy to a Strong Buy on February 13, following the company’s Q4 and FY report released a day earlier. In addition, the researcher increased his price target for Jazz Pharmaceuticals stock from $130 to $170.
- Bansal attributed their upgrade and price target hike to the recent IP settlement on the $1B Epidiolex franchise. The analyst explained that the deal de-risks Jazz Pharmaceuticals' long-term financials.
- Further, Bansal told readers, Wells Fargo sees a "high probability of success" for Zanidatamab for first-line GEA (gastroesophageal adenocarcinoma) trial, calling it a "potentially transformative catalyst" with a read-out expected in Q2 of this year.
- With a Zen Rating of A, JAZZ falls in the top 5% of stocks tracked by our proprietary ranking model — and stocks of this caliber have historically outperformed the market since the turn of the millennium. If that wasn’t enough of an endorsement, JAZZ is actually rated in the top 1%, so it belongs to an even more exclusive group of stocks.
- One thing that immediately jumps out is a rare blend of valuation and growth — Jazz Pharmaceuticals is in the top 1% of all stocks in terms of its Value Component Grade rating, and in the top 5% in terms of its Growth Component rating. Simply put, this is quite the undervalued stock — especially relative to its growth potential (See all 7 Zen Component Grades here >)
3- Wyndham Hotels & Resorts Inc (NYSE: WH)
We were surprised to find out that Wyndham Hotels & Resorts Inc is the largest hotel franchisor — not just in the United States, but in the entire world. It has some 9,200 locations spread out across 95 countries and operates a wide array of brands such as Ramada, Days Inn, Super 8, and La Quinta. However, the company’s focus isn’t on glitz and glamour — instead, the bread and butter driving the growth of WH stock is affordable, high-occupancy lodging — giving the company a stable cash flow that depends on limited capital expenditures.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $111.77 — get current quote >
Max 1-year forecast: $121.00
Why we’re watching:
- At present, 8 researchers are issuing ratings for WH stock — 6 have deemed it a Strong Buy, while 2 have given it a Buy rating. Notably, there are no Hold, Sell, or Strong Sell ratings to be found. See the ratings
- Wells Fargo’s Daniel Politzer (a top 9% rated analyst) affirmed a prior Strong Buy rating on February 14, after Wyndham Hotels & Resorts reported its Q4 and FY 2024 earnings.
- Politzer summarized the quarter with "EBITDA was in line and management's FY 2025 guidance beat consensus by 1%.
- Looking ahead, the analyst told readers that management's implied FY 2026 EBITDA is 4% above consensus but "meetable, and potentially beatable because of accelerating ancillary revenues, improving RevPAR trends, and higher FeePAR."
- On the same day, Brandt Montour of Barclays (a top 5% rated analyst) also maintained an earlier Strong Buy rating, while increasing his 12-month price forecast for WH stock from $116 to a Street-high $121.
- Montour said the print was headlined by accelerating RevPAR growth, ancillary fees, and market share gains. Further, the analyst said management's "strong" FY 2025 guidance "looks easily achievable."
- Stocks with a Zen Rating of B, like WY, have provided an average annual return of 19.88% since the early 2000s.
- Two of Wyndham Hotels & Resorts’ Component Grade ratings just jump off the page — Momentum and Financials. Both categories are rated B — indicating a strong balance sheet, as well as the presence of a strong uptrend. (See all 7 Zen Component Grades here >)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.